CG
YMAB

Cutler Group’s Y-mAbs Therapeutics YMAB Stock Holding History

Cutler Group’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,500
Closed -$1K – 4422
2023
Q2 		$1K Buy
+1,500
New +$11.2K ﹤0.01% 3460
2022
Q4 		– Sell
-1,000
Closed -$1K – 5368
2022
Q3 		$1K Sell
1,000
-1,100
-52% -$18.2K ﹤0.01% 4746
2022
Q2 		$5K Buy
2,100
+900
+75% +$10.5K ﹤0.01% 3779
2022
Q1 		$2K Buy
+1,200
New +$12.3K ﹤0.01% 4795

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Cutler Group's YMAB Position: Q4 2023 in Review

Cutler Group sold out of Y-mAbs Therapeutics (YMAB) in Q4 2023, closing a stake of 200 shares — an estimated $1K sold.

Cutler Group first reported a position in YMAB in Q3 2023 and held it in 1 quarter. The position peaked at $1K in Q3 2023. 94 funds tracked by Wall St. Rank hold YMAB as of Q4 2023.

  • Cutler Group reported no remaining Y-mAbs Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 200 Y-mAbs Therapeutics shares in Q4 2023, an estimated $1K.
  • Cutler Group first reported a position in Y-mAbs Therapeutics in Q3 2023 and held it in 1 quarter.
  • Cutler Group's Y-mAbs Therapeutics position peaked at $1K in Q3 2023.
  • 94 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.